Jianhua Luo
University of Pittsburgh School of Medicine, USA
Title: Genomic markers of prostate cancer
Biography
Biography: Jianhua Luo
Abstract
Despite a high incidence, only a fraction of men diagnosed with prostate cancer (PCa) develop metastases and even fewer die from the disease. The majority of prostate cancers remain asymptomatic and clinically indolent. The precise mechanisms for the development of progressive, clinically relevant PCa remain elusive. Recently, we found large numbers of copy number variations in the blood, benign prostate tissues and prostate cancer samples from prostate cancer patients. Interestingly, the sizes of CNVs in the blood samples of prostate cancer patients are highly correlated with the clinical outcomes in terms of prostate cancer recurrence and prostate cancer related death. Using least square regression model, we achieved 75% accuracy in predicting prostate cancer recurrence after radical prostatectomy using CNV information from the blood samples of prostate cancer patients, significantly higher than the prediction rates generated by Gleason scores or Nomogram. When blood CNV combined with the status of Nomogram and fusion gene, the accurate prediction rate is 87.6%. The blood CNV prediction model is of particular interest, since it offers an alternative in predicting prostate cancer clinical courses when radical prostatectomy is not performed, and nomogram information cannot be obtained. As a result, we conclude that the formation of large size germline CNVs predisposed patients to aggressive prostate cancer clinical courses.
